2009 Update to WIC Cost-Effective for Reducing Childhood Obesity
By Elana Gotkine HealthDay Reporter
TUESDAY, Jan. 23, 2024 -- The 2009 update to the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) was estimated to be cost-effective for preventing childhood obesity, according to a study published online Jan. 23 in Pediatrics.
Erica L. Kenney, Sc.D., M.P.H., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues estimated the impact of the 2009 WIC food package change on obesity risk for participating children aged 2 to 4 years from 2010 through 2019. The cases of obesity prevented in 2019 and costs per quality-adjusted-life year gained were estimated using microsimulation models.
The researchers found that an estimated 14.0 million U.S. children aged 2 to 4 years were reached by the updated WIC nutrition standards from 2010 through 2019. An estimated 62,700 cases of childhood obesity were prevented in 2019, all of which involved children from households with low incomes, thereby improving health equity. Per quality life-year gained, the update was estimated to cost $10,600. More than twice as many cases of childhood obesity would have been prevented if WIC had reached all eligible children.
"The WIC 2009 food package change is estimated to have reduced childhood obesity for children in households with low income and to be highly cost-effective while improving health equity," the authors write. "WIC's beneficial impact could be expanded by identifying strategies to increase enrollment and improve retention in the program."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-01-24 04:15
Read more
- Tenecteplase Has Similar Safety to TPA for Acute Ischemic Stroke
- Weed Use During Pregnancy May Harm Kids' Behavior, Thinking Skills
- Women, Men on Kidney Dialysis Face Different Heart Risks
- America's Epidemic of STDs May Finally Be Slowing
- Travel Time to Tanning Facilities Negatively Linked to Melanoma Incidence
- Fish Oil Supplements Might Help Prevent Cancer
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions